This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The topic of prior use has been elevated to the status of a referral to the Enlarged Board of Appeal ( G1/23 ). 25 sequence listing added to the pages of a divisional has now been issued ( OJ EPO 2023, A98 ). 26: Is it time for patent offices to enter the bioinformatic age? This is one to watch for 2024. Looking beyond ST.26:
In a noteworthy year for patentlaw, the U.S. Court of Appeals for the Federal Circuit issued several decisions that will shape the patent landscape and the Federal Rules of Evidence governing expert testimony were amended. Supreme Court and the U.S. By: Smith Anderson
It is also possible to patent the second medical use of a known drug, e.g. in a different disease or at a different dose ( Article 54(4) EP ). Importantly, under European patentlaw, a claim to a substance or composition for use in a method of treatment is construed to include the treatment effect as a functional feature.
Disclosure of Patentable Ideas To figure out if disclosing invention details to ChatGPT is a public disclosure under patentlaw, we need to see if it can be categorized as a description in a printed publication, publicuse, or public sale. enablement). The court in Hurry Family Revocable Tr.
Disclosure of Patentable Ideas To figure out if disclosing invention details to ChatGPT is a public disclosure under patentlaw, we need to see if it can be categorized as a description in a printed publication, publicuse, or public sale. enablement). The court in Hurry Family Revocable Tr.
Disclosure of Patentable Ideas To figure out if disclosing invention details to ChatGPT is a public disclosure under patentlaw, we need to see if it can be categorized as a description in a printed publication, publicuse, or public sale. enablement). The court in Hurry Family Revocable Tr.
Despite the EPO's continued insistence that the issue is settled ( IPKat ), we can expect the issue to rumble on into 2023. Artificial intelligence is not breaking patentlaw: EPO publishes DABUS decision (J 8/20) ST.26 26 ( IPKat ).
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content